About the Advanced Regenerative Manufacturing Institute
Our mission is to advance the bioeconomy of the United States. The Institute’s work will positively impact not only manufacturing but also healthcare and education and workforce development for the nation.
Manufacturing scalability, process and partnership.
There are 400,000 people worldwide right now on waiting lists for organs. What if we could create lungs, livers or corneas at scale? It would be unprecedented.
Our goal is to move highly specialized regenerative medicine – engineering or regenerating human cells, tissues and organs – from lab to production to cure diseases and improve quality of life.
ARMI’s Leadership Team
DEAN KAMEN
Executive Director & Chairman of the Board, ARMI
Maureen Toohey
Deputy Executive Director & Secretary of the Board
Thomas Bollenbach, Ph.D.
Chief Technology Officer
Jim Scott
Chief Administrative Officer
Jennifer MacDonald, M.D.
Chief Operating Officer
News Highlights
Events
Events
-
-
Accelerating the Translation of Cell Therapy for Type 1 Diabetes
The Lister Hill Center, Building 38A, Bethesda, MDARMI CTO Dr. Tom Bollenbach will moderate manufacturing and AI sessions at an NIH workshop focused on advancing cell-replacement therapies for type 1 diabetes.
-
Cell & Gene Therapy International 2026
Hynes Convention Center 900 Boylston Street, Boston, MA, United StatesJoin ARMI at Cell & Gene Therapy International during Biotech Week Boston, where Chief Regulatory Officer Dr. Richard McFarland will moderate a panel on decentralized manufacturing for cell therapies.
-
-
Cambridge Science Carnival
MIT/Kendall Open Space, 292 Main Street, Cambridge, MAMeet ARMI | BioFabUSA at the 2026 Cambridge Science Carnival and explore regenerative manufacturing, STEM education and biomanufacturing careers.
-
Cell & Gene Meeting on the Mesa 2026
Arizona Biltmore 2400 E Missouri Ave, Phoenix, AZ, United StatesARMI will attend the Cell & Gene Meeting on the Mesa 2026, one of the industry’s leading conferences focused on overcoming the commercialization, manufacturing, and investment challenges facing advanced therapies
